H.C. Wainwright sees ‘little room left for doubt’ on Cytokinetics’ aficamten

H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating and $120 price target on Cytokinetics (CYTK) after the company hosted an investor event to discuss new data related to aficamten that were presented at the European Society of Cardiology Congress, including primary results from the comparative Phase 3 MAPLE-HCM trial and longer-term efficacy and safety from the FORESTHCM extension study. Ahead of aficamten’s PDUFA date on December 26, the firm sees “little room left for doubt” and sees potential for the drug as “a next-in-class CMI for oHCM with a favorable label, as well as for additional label-expansion and quick adoption from future updated cardiomyopathy guidelines, the analyst tells investors.